Riganti C - Search Results

1

PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy.

Salaroglio IC, Panada E, Moiso E, Buondonno I, Provero P, Rubinstein M, Kopecka J, Riganti C. Salaroglio IC, et al. Among authors: riganti c. Mol Cancer. 2017 May 12;16(1):91. doi: 10.1186/s12943-017-0657-0. Mol Cancer. 2017. PMID: 28499449 Free PMC article.

2

Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux.

Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia A. Riganti C, et al. Cancer Res. 2005 Jan 15;65(2):516-25. Cancer Res. 2005. PMID: 15695394

3

Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin.

Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A. Miraglia E, et al. Among authors: riganti c. Int J Cancer. 2005 Jul 20;115(6):924-9. doi: 10.1002/ijc.20959. Int J Cancer. 2005. PMID: 15729714

4

Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells.

Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A. Riganti C, et al. Mol Pharmacol. 2008 Aug;74(2):476-84. doi: 10.1124/mol.108.045286. Epub 2008 May 7. Mol Pharmacol. 2008. PMID: 18463201

5

RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells.

Doublier S, Riganti C, Voena C, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A. Doublier S, et al. Among authors: riganti c. Mol Cancer Res. 2008 Oct;6(10):1607-20. doi: 10.1158/1541-7786.MCR-08-0251. Mol Cancer Res. 2008. PMID: 18922976

6

iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.

De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, Ghigo D, Bosia A, Riganti C. De Boo S, et al. Among authors: riganti c. Mol Cancer. 2009 Nov 19;8:108. doi: 10.1186/1476-4598-8-108. Mol Cancer. 2009. PMID: 19925669 Free PMC article.

7

Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells.

Kopecka J, Campia I, Brusa D, Doublier S, Matera L, Ghigo D, Bosia A, Riganti C. Kopecka J, et al. Among authors: riganti c. J Cell Mol Med. 2011 Jul;15(7):1492-504. doi: 10.1111/j.1582-4934.2010.01137.x. J Cell Mol Med. 2011. PMID: 20716130 Free PMC article.

8

A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells.

Kopecka J, Campia I, Olivero P, Pescarmona G, Ghigo D, Bosia A, Riganti C. Kopecka J, et al. Among authors: riganti c. J Control Release. 2011 Jan 20;149(2):196-205. doi: 10.1016/j.jconrel.2010.10.003. Epub 2010 Oct 12. J Control Release. 2011. PMID: 20946921

9

Pleiotropic effects of cardioactive glycosides.

Riganti C, Campia I, Kopecka J, Gazzano E, Doublier S, Aldieri E, Bosia A, Ghigo D. Riganti C, et al. Curr Med Chem. 2011;18(6):872-85. doi: 10.2174/092986711794927685. Curr Med Chem. 2011. PMID: 21182478 Review.

10

Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.

Riganti C, Voena C, Kopecka J, Corsetto PA, Montorfano G, Enrico E, Costamagna C, Rizzo AM, Ghigo D, Bosia A. Riganti C, et al. Mol Pharm. 2011 Jun 6;8(3):683-700. doi: 10.1021/mp2001389. Epub 2011 May 5. Mol Pharm. 2011. PMID: 21491921

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

293 results

Search Page

Filters